期刊文献+

Oxaliplatin and teniposide can inhibit the proliferation and induce the apoptosis of gastric cancer cell line BGC-823 synergistically 被引量:1

奥沙利铂联合替尼泊甙对胃癌BGC-823细胞的生长抑制和诱导凋亡的协同作用(英文)
下载PDF
导出
摘要 Objective:The aim of this study was to investigate the synergistic effects of oxaliplatin and teniposide on proliferation and apoptosis of gastric cancer cell line BGC-823.Methods:MTT assay was carried to examine the inhibition rate of oxaliplatin and teniposide on gastric cancer cell line BGC-823 with various concentrations separately and associatively.The apoptosis rate of BGC-823 cells under the treatment of oxaliplatin or/and teniposide was examined by flow cytometry.The expression level of livin, an apoptosis-associated protein, was explored by western blot.Results:Oxaliplatin or teniposide could remarkably inhibit the BGC-823 gastric cancer cell growth with a dose-response manner, separately and associatively.The inhibition rate of oxaliplatin combined with teniposide on BGC-823 cells was higher than that of single oxaliplatin or single teniposide(P < 0.05), with 0.46 as combination index(CI) value.The apoptosis rates of cells treated by oxaliplatin for 12 h, 24 h and 48 h were 6.13%, 13.86% and 21.48%, respectively, while which of teniposide were 4.60%, 10.72%, 17.07%.But when the two medicines were carried associatively, the apoptosis rates for 12 h, 24 h and 48 h were 11.73%, 24.14% and 44.75%, respectively.Western blot showed that the expression level of livin was more down-regulated when cells were treated by oxaliplatin + teniposide than by oxaliplatin singly.Conclusion:The combination of oxaliplatin and teniposide can exert a synergistic effect on gastric cancer cell BGC-823.
机构地区 Department of Oncology
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2010年第3期149-152,共4页 中德临床肿瘤学杂志(英文版)
关键词 gastric cancer OXALIPLATIN TENIPOSIDE APOPTOSIS flow cytometry 奥沙利铂 细胞凋亡 细胞增殖 细胞株 胃癌 协同作用 诱导
  • 相关文献

参考文献3

二级参考文献24

  • 1于朝春,周范民,王宇倩,钟平.脑胶质瘤的化疗敏感性研究[J].中华神经医学杂志,2005,4(7):686-690. 被引量:14
  • 2Munoz N,Franceschi S.Epidemiology of gastric cancer and perspectives for prevention.Salud Publica Mex 1997;39:318-330.
  • 3Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world.J Clin Oncol 2006;24:2137-2150.
  • 4Glimelius B,Ekstrom K,Hoffman K,Graf W,Sjodén PO,Haglund U,Svensson C,Enander LK,Linné T,Sellstrom H,Heuman R.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.Ann Oncol 1997;8:163-168.
  • 5Webb A,Cunningham D,Scarffe JH,Harper P,Norman A,Joffe JK,Hughes M,Mansi J,Findlay M,Hill A,Oates J,Nicolson M,Hickish T,O'Brien M,Iveson T,Watson M,Underhill C,Wardley A,Meehan M.Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer.J Clin Oncol 1997;15:261-267.
  • 6Wagner AD,Grothe W,Haerting J,Kleber G,Grothey A,Fleig WE.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data.J Clin Oncol 2006;24:2903-2909.
  • 7Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997.
  • 8Cunningham D,Starling N,Rao S,Iveson T,Nicolson M,Coxon F,Middleton G,Daniel F,Oates J,Norman AR.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med 2008;358:36-46.
  • 9Kang Y,Kang WK,Shin DB,Chen J,Xiong J,Wang J,Lichinitser M,Salas MP,Suarez T,Santamaria J.Randomized phase III trial of capecitabine/cisplatin (XP) vs.continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):efficacy and safety results.Proceedings of the 42nd Annual Meeting of American Society of Clinical Oncology;2006 June 1-5;Chicago,USA.Alexandria:American Society of Clinical Oncology,2006:18s.
  • 10Koizumi W,Narahara H,Hara T,Takagane A,Akiya T,Takagi M,Miyashita K,Nishizaki T,Kobayashi O,Takiyama W,Toh Y,Nagaie T,Takagi S,Yamamura Y,Yanaoka K,Orita H,Takeuchi M.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase III trial.Lancet Oncol 2008;9:215-221.

共引文献41

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部